Lupin sells its Japan injectables business to Neopharma

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Kritchanut)
(Image: Getty/Kritchanut)

Related tags: Lupin Pharmaceuticals, Neopharma, Injectables, facility, acquisition

Lupin to divest its Japanese injectables business to a subsidiary of Neopharma group in the UAE, aiming to streamline its Japan operations.

Under the agreement, Lupin, through its Japanese subsidiary Kyowa Pharmaceutical Industry, will sell all shares of its injectables business, Kyowa Criticare, to neo ALA, a wholly owned subsidiary of Neopharma group headquartered in Abu Dhabi, United Arab Emirates (UAE).

Kyowa Criticare is a manufacturer of injectable products, with facilities in Atsugi, Japan. According to Lupin, the transaction will not affect other operations of Kyowa, which include research, manufacturing, and marketing of oral solids and other dosage forms in Japan.

Fabrice Egros, president of Lupin in Asia Pacific, said the divestiture is “a step towards streamlining our Japan operations and bringing sharper focus on building a hybrid (Brand/ generics) pharma model in Japan.”

On his side, Suresh Nandiraju, COO of Neopharma, said that the acquisition will strengthen the company’s offering in the Japanese market, where Neopharma anticipates sustainable growth.

Financial details of the transaction were not disclosed. 

Neopharma is the largest pharmaceutical manufacturer in the UAE, and has been taking steps forward over the last year with the acquisitions of facilities from Dr Reddy’s in India​ and the US​.

The company also recently announced​ an agreement for the commercialization and distribution of six drug products of GlaxoSmithKline in the UAE.

The deal with Neopharma comes as Lupin is facing several regulatory blockages​ regarding its operations at its facilities in India.

Earlier this year​, the US Food and Drug Administration issued Lupin a Form 483, regarding concerns about microbial contamination, including a report about human hair found embedded in a tablet.

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...


Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers